Stereotactic Thalamotomy – A Conventional But A Valuable and Effective Surgical Strategy for Parkinsonian Tremors
Objective: To determine the frequency of improvement in tremors in Parkinsonian patients after stereotactic thalamotomy.
Material & Methods: A descriptive case series was conducted in the department of Neurosurgery Unit II, Lahore General Hospital from January 2016 to March 2020. The study included65 patients of Parkinson’s disease with tremors refractory to medicines for 6 months who fulfilled the inclusion criteria. Outcome and possible complications were explained before taking informed consent. An outcome like reduction in tremors was used as a research instrument. It was determined by a modified unified Parkinson's disease rating score (UPDRS). Patients were diagnosed based on history, clinical examination, and MRI brain by a team comprising of neurologists and neurosurgeons. Thalamotomy was done by one surgical team. Patients were examined and scored post-operatively at 3 weeks and 3 months. Improvement was labeled as a reduction in tremors upto grade 1 or more from baseline after thalamotomy.
Results: Improvement in tremors after thalamotomy was observed in 58.5% of patients whereas there was no improvement in tremors after thalamotomy in 41.5% of patients. There was no significant association between age and improvement in tremors after thalamotomy (p-value = 0.786). No significant association was found between the duration of medical treatment and improvement in tremors after thalamotomy (p-value = 0.681).
Conclusion: Improvement in tremors after thalamotomy was observed in 58.5% of parkinsonian patients. Effect modifiers like age and duration of medical treatment were not significantly associated with improvement in tremors after thalamotomy.
2. Balestrino R, Schapira AHV. Parkinson disease. European Journal of Neurology, 2020; 27 (1): 27–42.
3. Tysnes O-B, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm (Vienna), 2017; 124 (8): 901–5.
4. GBD 2016 Parkinson’s Disease Collaborators. Global, regional, and national burden of Parkinson’s disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018; 17 (11): 939–53.
5. Rizek P, Kumar N, Jog MS. An update on the diagnosis and treatment of Parkinson disease. CMAJ. 2016; 188 (16): 1157–65.
6. Ahmed H, Field W, Hayes MT, Lopez WOC, McDannold N, Mukundan S Jr, et al. Evolution of movement disorders surgery leading to contemporary focused ultrasound therapy for tremor. Magn Reson Imaging Clin N Am. 2015; 23 (4): 515–22.
7. Dwarakanath S, Zafar A, Yadav R, Arivazhagan A, Netravathi M, Sampath S, et al. Does lesioning surgery have a role in the management of multi-etiological tremor in the era of Deep Brain Stimulation? Clin Neurol Neurosurg. 2014; 125: 131–6.
8. Chao Y, Gang L, Na ZL, Ming WY, Zhong WS, Mian WS. Surgical management of Parkinson’s disease: update and review. Interv Neuroradiol. 2007; 13 (4): 359–68.
9. Tasker RR. Tremor of parkinsonism and stereotactic thalamotomy. Mayo Clin Proc. 1987; 62 (8): 736–9.
10. Fox MW, Ahlskog JE, Kelly PJ. Stereotactic ventrolateralis thalamotomy for medically refractory tremor in post-levodopa era Parkinson’s disease patients. J Neurosurg. 1991; 75 (5): 723–30.
11. Sobstyl M, Zabek M, Koziara H, Kadziołka B, Mossakowski Z. Unilateral thalamotomy for the treatment of tremor dominant Parkinson’s disease. Neurol Neurochir Pol. 2006; 40 (2): 119–26.
12. Matsumoto K, Shichijo F, Fukami T. Long-term follow-up review of cases of Parkinson’s disease after unilateral or bilateral thalamotomy. J Neurosurg. 1984; 60 (5): 1033–44.
13. Jankovic J, Cardoso F, Grossman RG, Hamilton WJ. Outcome after stereotactic thalamotomy for parkinsonian, essential, and other types of tremor. Neurosurgery, 1995; 37 (4): 680–7.
14. Goldman MS, Ahlskog JE, Kelly PJ. The symptomatic and functional outcome of stereotactic thalamotomy for medically intractable essential tremor. J Neurosurg, 1992; 76 (6): 924–8.
15. Pan L, Zhang N, Wang EM, Wang BJ, Dai JZ, Cai PW. Gamma knife radiosurgery as a primary treatment for prolactinomas. J Neurosurg, 2000; 93 Suppl. 3: 10–3.
Copyright (c) 2021 Pakistan Journal Of Neurological Surgery
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.